GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Land And Improvements

4basebio (XTER:88Q) Land And Improvements : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Land And Improvements?

4basebio's land and improvements for the quarter that ended in Jun. 2023 was €0.00 Mil.


4basebio Land And Improvements Historical Data

The historical data trend for 4basebio's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Land And Improvements Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Land And Improvements
- - - -

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Land And Improvements Get a 7-Day Free Trial - - - - -

4basebio Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


4basebio (XTER:88Q) Business Description

Traded in Other Exchanges
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines